An IL-1.beta. binding molecule, in particular an antibody to human IL-1.beta.,especially a humanantibody to human IL-1.beta. is provided, wherein the CDRs of the heavy andlight chains have aminoacid sequences as defined, for use in the treatment of an IL-1 mediateddisease or disorder, e. g,osteoarthritis, osteoporosis and other inflammatory arthritides.